- Home
- CMRC vs AVTX Comparison
CMRC vs AVTX Comparison
Compare CMRC & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CMRC | AVTX |
|---|---|---|
| Founded | 2009 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 271.4M | 248.3M |
| IPO Year | 2020 | 2015 |
Fundamental Metrics
Financial Performance| Metric | CMRC | AVTX |
|---|---|---|
| Price | $2.75 | $14.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | $5.75 | ★ $34.50 |
| AVG Volume (30 Days) | ★ 1.5M | 387.9K |
| Earning Date | 02-12-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $342,349,000.00 | $192,000.00 |
| Revenue This Year | $6.41 | N/A |
| Revenue Next Year | $4.67 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2.83 | N/A |
| 52 Week Low | $2.41 | $3.39 |
| 52 Week High | $7.50 | $20.72 |
Technical Indicators
Market Signals| Indicator | CMRC | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 32.83 | 43.00 |
| Support Level | $2.41 | $13.50 |
| Resistance Level | $3.07 | $14.81 |
| Average True Range (ATR) | 0.20 | 1.12 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 41.86 | 32.45 |
Price Performance
Historical ComparisonAbout CMRC Commerce.com Inc.
Commerce.com Inc is engaged in offering Software-as-a-service (SaaS) e-commerce platform. The company's SaaS platform engages in the creation of online stores by delivering a combination of ease-of-use, enterprise functionality, and flexibility. It powers both the customers' branded ecommerce stores and their cross-channel connections to popular online marketplaces, social networks, and offline point-of-sale systems. The group operates in a single segment covering geographical areas of Americas-U.S.; Americas-other; EMEA; and APAC, of which majority of its revenue is generated from Americas-U.S.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).